Gilead Sciences Inc. (NASDAQ:GILD) shares traded up 1.6% during trading on Wednesday . The company traded as high as $80.69 and last traded at $80.55, with a volume of 5,593,554 shares trading hands. The stock had previously closed at $79.25.

A number of research analysts have commented on the stock. Royal Bank Of Canada restated a “buy” rating on shares of Gilead Sciences in a research note on Saturday, April 30th. Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, April 29th. Credit Suisse Group AG reiterated an “outperform” rating and set a $120.00 price target (up from $116.00) on shares of Gilead Sciences in a research note on Thursday, April 28th. Oppenheimer Holdings Inc. reiterated a “buy” rating and set a $116.00 price target (down from $120.00) on shares of Gilead Sciences in a research note on Wednesday, May 4th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Gilead Sciences in a research note on Saturday, May 14th. Ten investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $107.37.

The stock has a market capitalization of $106.35 billion and a price-to-earnings ratio of 7.07. The firm’s 50-day moving average is $82.95 and its 200 day moving average is $87.39.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, beating analysts’ consensus estimates of $3.02 by $0.06. During the same period last year, the company earned $3.15 earnings per share. The company earned $7.78 billion during the quarter, compared to the consensus estimate of $7.80 billion. The business’s revenue was down 5.7% compared to the same quarter last year. Analysts anticipate that Gilead Sciences Inc. will post $11.78 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Friday, September 16th will be paid a $0.47 dividend. The ex-dividend date is Wednesday, September 14th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.33%.

In related news, Chairman John C. Martin sold 100,000 shares of the business’s stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $84.73, for a total value of $8,473,000.00. Following the completion of the transaction, the chairman now directly owns 4,119,727 shares in the company, valued at approximately $349,064,468.71. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul Rutherford Carter sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $79.81, for a total value of $159,620.00. Following the completion of the transaction, the executive vice president now owns 64,122 shares of the company’s stock, valued at $5,117,576.82. The disclosure for this sale can be found here.

Other institutional investors have modified their holdings of the company. Sfmg LLC raised its position in shares of Gilead Sciences by 5.2% in the fourth quarter. Sfmg LLC now owns 10,619 shares of the biopharmaceutical company’s stock valued at $1,075,000 after buying an additional 522 shares in the last quarter. Mizuho Trust & Banking Co. Ltd. raised its position in shares of Gilead Sciences by 1.0% in the fourth quarter. Mizuho Trust & Banking Co. Ltd. now owns 2,277,664 shares of the biopharmaceutical company’s stock valued at $232,686,000 after buying an additional 23,105 shares in the last quarter. TMD & Associates Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter valued at about $2,539,000. Synovus Financial Corp raised its position in shares of Gilead Sciences by 8.0% in the fourth quarter. Synovus Financial Corp now owns 98,651 shares of the biopharmaceutical company’s stock valued at $9,964,000 after buying an additional 7,307 shares in the last quarter. Finally, Edgemoor Investment Advisors Inc. raised its position in shares of Gilead Sciences by 1.1% in the fourth quarter. Edgemoor Investment Advisors Inc. now owns 176,263 shares of the biopharmaceutical company’s stock valued at $17,836,000 after buying an additional 1,857 shares in the last quarter.

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.